Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Hosted on MSN
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Shares of early-stage biotech stocks, including Biohaven (NYSE: BHVN), Recursion Pharmaceuticals (NASDAQ: RXRX), and CRISPR Therapeutics (NASDAQ: CRSP), plunged in March, with the stocks down 35.3%, ...
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG stands among them. CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneering ...
To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...
Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback